Open AccessCombination of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 are biomarkers for the detection of colon tubular adenocarcinoma
Author(s) -
Jun Yuan,
Li-Shuang Xie,
Yanyan Zhu,
Xiaohua Wang,
Yijing Zhang,
Xiaojun Wang
Publication year - 2021
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v13.i10.1506
Subject(s) - lipocalin , medicine , adenocarcinoma , matrix metalloproteinase , immunohistochemistry , pathology , biomarker , downregulation and upregulation , cancer research , carcinogenesis , stage (stratigraphy) , immunoassay , cancer , immunology , biology , antibody , paleontology , biochemistry , gene
Tubular adenocarcinoma of the colon, which originates from the epithelium of the glands, is a major health concern worldwide. However, it is difficult to detect at an early stage. The lack of biomarkers is a main barrier to the diagnosis and treatment of tubular adenocarcinoma. Neutrophil gelatinase-associated lipocalin (NGAL) is a secreted protein that induces the expression of matrix metalloproteinase-9 (MMP-9) and is involved in various tumors. NGAL and MMP-9 have been reported to be associated with tumorigenesis and development. They may have potential as biomarkers for diagnosis of tubular adenocarcinoma of the colon.